Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02194738 · ClinicalTrials.gov registry record · NA

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

A NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

Active
Registry status
NA
Development phase
8,300
Enrollment target
20
Study locations

NCT02194738: Active NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

NCT02194738 is a NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 8,300 participants, above the 183-participant average among 31 other Stage IIIB Lung Cancer AJCC v8 trials with a reported enrollment target (4436% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02194738, a NA study of Stage IIIB Lung Cancer AJCC v8 and Stage IIIA Lung Cancer AJCC v8, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
8,300 participants
Enrollment target
20
Study locations

Study Summary

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Primary Outcome

Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, will be measured by the rate of accrual.

Conditions Studied

Stage IIIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Stage IIIA Lung Non-Small Cell Cancer AJCC v7 Stage IB Lung Non-Small Cell Carcinoma AJCC v7 Stage II Lung Non-Small Cell Cancer AJCC v7

Interventions

  • DRUG Carboplatin
  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • DRUG Cisplatin
  • OTHER Clinical Observation

Study Locations (20)

Alaska

  • Anchorage Associates in Radiation Medicine - Anchorage
  • Anchorage Radiation Therapy Center - Anchorage
  • Alaska Breast Care and Surgery LLC - Anchorage
  • Alaska Oncology and Hematology LLC - Anchorage
  • Alaska Regional Hospital - Anchorage
  • Alaska Women's Cancer Care - Anchorage
  • Anchorage Oncology Centre - Anchorage
  • Katmai Oncology Group - Anchorage
  • Providence Alaska Medical Center - Anchorage
  • Fairbanks Memorial Hospital - Fairbanks

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham
  • Southern Cancer Center PC-Daphne - Daphne
  • Southern Cancer Center PC-Mobile - Mobile
  • Southern Cancer Center PC-Providence - Mobile
  • Southern Cancer Center PC-Springhill - Mobile

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Kingman Regional Medical Center - Kingman
  • Cancer Center at Saint Joseph's - Phoenix
  • Banner-University Medical Center Phoenix - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix

Trial Details

FieldValue
Enrollment Target 8,300 participants
Start Date 2014-09-26
Est. Completion 2026-09-28
Phase NA
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02194738 still lists

NCT02194738 is an interventional study that assigns participants to a tested intervention. Its 8,300 participants enrollment target places it among the larger protocols in the corpus, above the 183-participant average among 31 other Stage IIIB Lung Cancer AJCC v8 trials with a reported enrollment target (4436% higher).

The record links to 7 conditions, with Stage IIIB Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT02194738 names 20 study sites across 3 states, led by Alaska, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT02194738 about?

NCT02194738 is a clinical study titled "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)". This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

What is the current status of trial NCT02194738?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 8,300 participants. The study started on 2014-09-26. Estimated completion is 2026-09-28.

What conditions does trial NCT02194738 study?

This clinical trial studies the following conditions: Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7.

What interventions are being tested in trial NCT02194738?

The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Cisplatin (DRUG), Clinical Observation (OTHER).

Who is sponsoring clinical trial NCT02194738?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02194738 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IIIB Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02194738's enrollment target sits among peer trials

8,300 1st of 31 higher than 31 of 31 other Stage IIIB Lung Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IIIB Lung Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07185828 · 8,286 participants · NA

    Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)

  • NCT06435806 · 8,200 participants · NA

    Medical Illustration Design Characteristic Evaluation

  • NCT06184945 · 8,100 participants · NA

    Behavioral Economic & Staffing Strategies in the ICU

  • NCT05593484 · 8,060 participants · NA

    School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02194738, the US trial registry maintained by the National Library of Medicine. NCT02194738 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.